Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines.
Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines.
复制标题
DOI：
10.1136/rmdopen-2020-001553
复制
发表时间：
2021-03
期刊：
影响因子：
6.2
通讯作者：
Skapenko A
中科院分区：
文献类型：
--
作者：
Schulze-Koops H;Specker C;Skapenko A
针对SARS-CoV-2的疫苗已经可用，有望结束目前的大流行。可以理解的是，患有炎症性风湿病（iRMD）的患者和他们的医生狂热地关注有关疫苗接种和SARS-CoV-2疫苗的问题。然而，由于所有iRMD患者都需要数月时间才能获得疫苗，因此现在为提高疫苗的潜在安全性和有效性而采取的措施可能会给患者带来潜在iRMD再激活的风险。特设委员会“Covid-19”和德国流变学学会董事会已经讨论了这一主题，并制定了考虑因素，旨在回答紧急问题，消除担忧和恐惧，并为iRMD患者提供初步建议。
Vaccination against SARS-CoV-2 has become available and will hopefully end the current pandemic. Understandably, patients with inflammatory rheumatic diseases (iRMDs) and their physicians are feverishly preoccupied with questions about vaccination and the vaccines against SARS-CoV-2. However, as it will take months before all patients with iRMDs will have access to the vaccines, measures that are taken now in order to increase potential safety and efficacy of the vaccines may impose a risk for the patients with regard to reactivation of their underlying iRMD. The ad hoc commission ‘Covid-19’ and the board of directors of the German Society for Rheumatology have addressed this topic and have developed considerations, which are intended to answer urgent questions, to take away concerns and fears and to make initial recommendations for patients with iRMDs.
登录
查看更多内容
DOI：
10.1016/s0140-6736(20)32661-1
发表时间：
2021-01-09
期刊：
Lancet (London, England)
影响因子：
--
作者：
Voysey M;Clemens SAC;Madhi SA;Weckx LY;Folegatti PM;Aley PK;Angus B;Baillie VL;Barnabas SL;Bhorat QE;Bibi S;Briner C;Cicconi P;Collins AM;Colin-Jones R;Cutland CL;Darton TC;Dheda K;Duncan CJA;Emary KRW;Ewer KJ;Fairlie L;Faust SN;Feng S;Ferreira DM;Finn A;Goodman AL;Green CM;Green CA;Heath PT;Hill C;Hill H;Hirsch I;Hodgson SHC;Izu A;Jackson S;Jenkin D;Joe CCD;Kerridge S;Koen A;Kwatra G;Lazarus R;Lawrie AM;Lelliott A;Libri V;Lillie PJ;Mallory R;Mendes AVA;Milan EP;Minassian AM;McGregor A;Morrison H;Mujadidi YF;Nana A;O'Reilly PJ;Padayachee SD;Pittella A;Plested E;Pollock KM;Ramasamy MN;Rhead S;Schwarzbold AV;Singh N;Smith A;Song R;Snape MD;Sprinz E;Sutherland RK;Tarrant R;Thomson EC;Török ME;Toshner M;Turner DPJ;Vekemans J;Villafana TL;Watson MEE;Williams CJ;Douglas AD;Hill AVS;Lambe T;Gilbert SC;Pollard AJ;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
6.2
作者：
Hasseli R;Mueller-Ladner U;Schmeiser T;Hoyer BF;Krause A;Lorenz HM;Regierer AC;Richter JG;Strangfeld A;Voll RE;Pfeil A;Schulze-Koops H;Specker C
通讯作者：
Specker C
DOI：
10.1056/nejmoa2027906
发表时间：
2020-12-17
期刊：
The New England journal of medicine
影响因子：
--
作者：
Walsh EE;Frenck RW Jr;Falsey AR;Kitchin N;Absalon J;Gurtman A;Lockhart S;Neuzil K;Mulligan MJ;Bailey R;Swanson KA;Li P;Koury K;Kalina W;Cooper D;Fontes-Garfias C;Shi PY;Türeci Ö;Tompkins KR;Lyke KE;Raabe V;Dormitzer PR;Jansen KU;Şahin U;Gruber WC
通讯作者：
Gruber WC
影响因子：
120.7
作者：
van der Made, Caspar I.;Simons, Annet;Hoischen, Alexander
通讯作者：
Hoischen, Alexander